论文部分内容阅读
为研究血脂康的长期疗效与安全性,对38例持续服用血脂康达24周的原发性高脂血症患者,进行血脂与安全性指标的监测。服药24周后血清总胆固醇(TC)水平降低20.0％,低密度脂蛋白胆固醇(LDL—C)水平降低27.2％,甘油三酯(TG)水平降低31.6％,高密度脂蛋白胆固醇(HDL—C)水平升高15.7％。上述各指标与治疗前比较均有显著性差异(P<0.001～0.01)。服药24周调节TC、TG及HDL—C的个体疗效分别为80.0％、66.7％、61.5％。服药24周后患者体重、血压、EKG、ALT、CK、BUN、Cr、BS等与服药前比较均无明显变化(P>0.05)。患者服药耐受性好,无明显不良反应。提示血脂康治疗半年以上不仅疗效显著、稳定,而且安全。
In order to study the long-term efficacy and safety of Xuezhikang, blood lipid and safety indexes were monitored in 38 patients with hyperlipidemia who had been taking Xuezhikang for 24 weeks. Serum total cholesterol (TC) levels decreased by 20.0%, low density lipoprotein cholesterol (LDL-C) levels decreased by 27.2%, triglyceride (TG) levels decreased by 31.6% and high density lipoprotein cholesterol ) Increased by 15.7%. The above indicators and before treatment were significantly different (P <0.001 ~ 0.01). The individual curative effects of TC, TG and HDL-C at the age of 24 weeks were 80.0%, 66.7% and 61.5% respectively. The body weight, blood pressure, EKG, ALT, CK, BUN, Cr, BS, etc. in patients after 24 weeks of medication did not change significantly compared with those before medication (P> 0.05). Patient medication tolerance, no obvious adverse reactions. Tip Xuezhikang more than six months of treatment is not only significant, stable, but also safe.